P741: Patients’ Perspectives on Oral Decitabine and Cedazuridine for the Treatment of Myelodysplastic Syndromes
Year: 2023
Type: article
Study design: Observational Study
Abstract: Background: Hypomethylating agents (HMAs) are guideline-recommended treatment for higher-risk myelodysplastic syndromes (MDS). However, a prior patient survey (Zeidan, 2022) reported challenges with intravenous/subcutaneous (IV/SC) HMA therapy, including pain related to treatment administration and interference with daily activities. Aims: This study evaluated the perspectives of MDS patients receiving oral decitabine and cedazuridine (DEC-C), an alternative to IV/SC HMAs. Methods: An online survey was conducted among adult patients with MDS in the US (11/2022─12/2022) who had filled a prescription for DEC-C between 2021–2022. Results: A total of 150 patients completed the survey (61% aged ≥60 years, 63% male). Of these, 123 (82%) were still receiving DEC-C and 27 (18%) had stopped treatment. Half (50%) of patients had received DEC-C for ≥6 months. The majority reported that treatment was convenient (83%) and that they were satisfied with treatment (86%). Most patients also reported very little/no interference with regular daily activities (82%), social activities (79%), and productivity (78%). When queried about negative impacts on quality-of-life, treatment side-effects were the most commonly reported (30% of respondents). Among patients who had previously received IV/SC HMAs (n=91), most agreed that DEC-C interfered less with daily life (91%) and had experienced improvement in quality-of-life (85%) compared with previous treatment; 91% reported that DEC-C reduced the number of times they needed to travel to a healthcare facility (Figure). Summary/Conclusion: Survey results suggest very little/no impact on regular daily activities and improved quality-of-life with oral DEC-C relative to IV/SC HMAs, highlighting the potential for DEC-C to reduce the treatment burden associated with parenteral HMA therapy.Keywords: Oral, Hypomethylating agents, Myelodysplastic syndrome, Quality of life
Source: HemaSphere
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,480
OpenAlex ID: W4385667589